Top Markets
#1 Cortex Cortex +32.55%
#2 龙虾 (Lobster) 龙虾 (Lobster) +16.86%
#3 Akedo Akedo +12.21%
#4 wojak wojak +11.93%
#5 MarsCoin MarsCoin +11.23%
#6 Pons Pons +10.45%
#7 EXOD EXOD +9.04%
#8 The Black Bull The Black Bull +7.87%
#9 Seeker Seeker +7.61%
#10 Official Trump Official Trump +6.67%
Coin of the day
Cortex Cortex
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Ambrx Biopharma Inc. Ambrx Biopharma Inc.

Ambrx Biopharma Inc.

AMAM
Peringkat dalam Saham #6974
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused... Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.
Harga Saham
$28.00
Terakhir disinkronkan: 2024-03-06
Kapitalisasi Pasar
$1.77B
Perubahan (1 hari)
0.07%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Ambrx Biopharma Inc. (AMAM)

Kategori

Healthcare
Rasio P/E untuk Ambrx Biopharma Inc. (AMAM)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Ambrx Biopharma Inc., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Ambrx Biopharma Inc. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.